Selinexor: all 154 studies that test it
Page 2 of 2. Open to participants first (46), then studies with results posted, then the rest; newest registration first within each.
- Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT05322330Phase 2
- A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHLTerminatedNCT05265975Phase 1/2
- A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple MyelomaStatus unknownNCT05201118Phase 1
- Selinexor Combination Ph 1 StudyWithdrawnNCT05177276Phase 1/2
- A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)SuspendedNCT05099003Phase 1/2
- A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple MyelomaActive, not recruitingNCT05028348Phase 3
- A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )Status unknownNCT04998760Phase 2
- Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory DiseaseWithdrawnNCT04984330Early Phase 1
- Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaActive, not recruitingNCT04898894Phase 1
- Selinexor in Combination With Thalidomide and Dexamethasone in RRMMStatus unknownNCT04891744Phase 1/2
- A Study of Different Dosing Schedules of Selinexor in Sarcoma PatientsCompletedNCT04811196Phase 1
- Study of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04782687Phase 2
- Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM PatientsActive, not recruitingNCT04717700Phase 2
- Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple MyelomaCompletedNCT04640779Phase 1
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisActive, not recruitingNCT04562870Phase 2
- Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisActive, not recruitingNCT04562389Phase 3
- COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;CompletedNCT04534725Phase 3
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingNCT04442022Phase 2/3
- Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19WithdrawnNCT04355676Phase 2
- Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)Active, not recruitingNCT04138381Phase 1/2
- Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic MalignanciesCompletedNCT03955783Phase 1
- Selinexor in Combination With Ixazomib for the Treatment of Advanced SarcomaWithdrawnNCT03880123Phase 1
- Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
- Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AMLCompletedNCT03661515Phase 1
- SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple MyelomaActive, not recruitingNCT03589222Phase 2
- Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]CompletedNCT03555422Phase 3
- Selinexor in Patients With Advanced Thymoma and Thymic CarcinomaStatus unknownNCT03466827Phase 2
- Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell LymphomaCompletedNCT03212937Phase 1
- Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin LymphomaActive, not recruitingNCT03147885Phase 1/2
- Study of Selinexor and Doxorubicin in Advanced Soft Tissue SarcomasCompletedNCT03042819Phase 1
- Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia PatientsActive, not recruitingNCT02835222Phase 2
- A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With MyelomaCompletedNCT02831686Phase 1
- A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDPCompletedNCT02741388Phase 1
- Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple MyelomaWithdrawnNCT02628704Phase 2
- Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid LeukemiaCompletedNCT02573363Phase 1
- Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung CancerWithdrawnNCT02536495Phase 1/2
- Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After TransplantCompletedNCT02485535Phase 1
- KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell LymphomaCompletedNCT02471911Phase 1
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaActive, not recruitingNCT02436707Phase 2
- Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome PatientsWithdrawnNCT02431351Phase 2
- A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AMLCompletedNCT02403310Phase 1
- Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsWithdrawnNCT02389543Phase 1/2
- Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) PatientsWithdrawnNCT02367690Phase 1/2
- Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal EsophagusTerminatedNCT02283359Phase 1
- Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial CancersCompletedNCT02269293Phase 1
- KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic TumorsCompletedNCT02250885Phase 2
- Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT02227251Phase 2
- Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic SyndromeCompletedNCT02212561Phase 1
- Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02199665Phase 1
- Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By SurgeryCompletedNCT02120222Phase 1
- Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02093403Phase 1
- Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AMLActive, not recruitingNCT02091245Phase 1
- Phase I Study of KPT330 in Asian PatientsCompletedNCT02078349Phase 1
- A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of GenesCompletedNCT02069730Not applicable